Tranexamic acid
Based on 1 publication(s) in Google Scholar
Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis. Tranexamic acid is a PROTAC linker. Tranexamic acid is used to synthesize PROTACs (e.g. LZ-07 (HY-172590)).
For research use only. We do not sell to patients.
- Purity: 99.88%
- CAS No.: 1197-18-8
- Formula: C8H15NO2
- Molecular Weight:157.21
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Tranexamic acid
MoreAll AMPK Isoforms
MoreAll PROTAC Linkers Isoforms
More
Biological Activity
|
MMP-1 |
Tranexamic acid (20-100 μg/mL, 24 h) attenuates the effects of severe trauma by enhancing mitochondrial respiration, suppressing damage-associated molecular patterns (DAMPs) release and improving capillary integrity in human umbilical vein endothelial cells (HUVECs) and human arterial endothelial cells (HAECs)[1].
Tranexamic acid (0.2-5 mM, 30 min) inhibits cell migration of MDA-MB-231 BAG breast cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231
-
Concentration:0.2 mM, 1 mM, 5mM
-
Incubation Time:30 min
-
Result:Significantly inhibits cell migration with the inhibition of 26% ± 8.4% at 0.2 mM and 40% ± 4.2% at 1 mM.
Tranexamic acid (750 mg/kg, p.o., once a day for 20 consecutive days) decreases the proliferation of mast cells and increases the proliferation of fibroblasts, subsequently improving wrinkles caused by skin dryness in mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Traumatic brain injury (TBI) mice[3]
-
Dosage:100 mg/kg
-
Administration:Intravenous injection (i.v.)
-
Result:Inhibited local plasmin formation and fibrinolysis.
Impacts on the local immune response following TBI.
Did not enhance reactivity of cervical lymph node (cLN) cells to central nervous system (CNS) antigens.
Influences the cellular immune profile of peripheral lymph nodes.
Reduced microglial and macrophage activation.
-
Animal Model:Skin dryness induced wrinkles mice[4]
-
Dosage:750 mg/kg
-
Administration:Oral
-
Result:Resulted in the amelioration of transepidermal water loss (TEWL) and moisture retention.
Suppressed the generation of wrinkles.
Inhibited plasma concentrations of adrenocorticotropic hormone (ACTH), corticosterone, and IgE.
Suppressed proliferation of mast cells.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1197-18-8
-
Appearance Solid
-
Molecular Weight 157.21
-
Formula C8H15NO2
-
Color White to off-white
-
SMILES
O=C([C@H]1CC[C@H](CN)CC1)O
-
Synonyms
cyclocapron
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
H2O : 50 mg/mL (318.05 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (636.09 mM); Clear solution; Need ultrasonic
Purity & Documentation
-
Data Sheet (296 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Prudovsky I, et al. Tranexamic acid suppresses the release of mitochondrial DNA, protects the endothelial monolayer and enhances oxidative phosphorylation [J]. Journal of cellular physiology, 2019, 234(11): 19121-19129. [Content Brief]
[2]. Wu G, et al. Tranexamic acid is an active site inhibitor of urokinase plasminogen activator [J]. Blood advances, 2019, 3(5): 729-733. [Content Brief]
[3]. Draxler D F, et al. Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis [J]. Journal of Thrombosis and Haemostasis, 2019, 17(12): 2174-2187. [Content Brief]
[4]. Hiramoto K, et al. The amelioration effect of tranexamic acid in wrinkles induced by skin dryness [J]. Biomedicine & Pharmacotherapy, 2016, 80: 16-22. [Content Brief]
[5]. Sindet-Pedersen S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery [J]. New England Journal of Medicine, 1989, 320(13): 840-843. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 6.3609 mL | 31.8046 mL | 63.6092 mL | 159.0230 mL |
| 5 mM | 1.2722 mL | 6.3609 mL | 12.7218 mL | 31.8046 mL | |
| 10 mM | 0.6361 mL | 3.1805 mL | 6.3609 mL | 15.9023 mL | |
| 15 mM | 0.4241 mL | 2.1203 mL | 4.2406 mL | 10.6015 mL | |
| 20 mM | 0.3180 mL | 1.5902 mL | 3.1805 mL | 7.9511 mL | |
| 25 mM | 0.2544 mL | 1.2722 mL | 2.5444 mL | 6.3609 mL | |
| 30 mM | 0.2120 mL | 1.0602 mL | 2.1203 mL | 5.3008 mL | |
| 40 mM | 0.1590 mL | 0.7951 mL | 1.5902 mL | 3.9756 mL | |
| 50 mM | 0.1272 mL | 0.6361 mL | 1.2722 mL | 3.1805 mL | |
| 60 mM | 0.1060 mL | 0.5301 mL | 1.0602 mL | 2.6504 mL | |
| 80 mM | 0.0795 mL | 0.3976 mL | 0.7951 mL | 1.9878 mL | |
| 100 mM | 0.0636 mL | 0.3180 mL | 0.6361 mL | 1.5902 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz